Flamingo Pharmaceuticals Limited

Flamingo Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U51900MH1985PLC036572 Incorporated 12 June 1985 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹636.88 Cr
▲ 25% YoY
Net profit · FY 2026
₹96.92 Cr
Net margin 15.2%
EBITDA · FY 2026
₹160.57 Cr
EBITDA margin 25.2%
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹6.8 Cr
Issued & subscribed
Open charges
₹121.37 Cr
Satisfied ₹452.45 Cr
Company age
41 yrs
Est. 1985
Employees · EPFO
552
Provident fund records

About Flamingo Pharmaceuticals Limited

Data last updated:

Flamingo Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 June 1985 and has been in existence for over 41 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51900MH1985PLC036572. Its GSTIN is 27AAACF4211B1ZE (Maharashtra). The company holds 9 GST registrations, of which 1 is active.

The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹6.8 Cr. It was formerly known as Flamingo Impex Limited and Flamingo Impex P Limited. It is led by directors including Parth Ashwin Thacker and Chhotulal Rawa Bhagwat.

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1 Corporate Park, Mumbai, Maharashtra.

As per the financials filed for FY 2026, the company reported a revenue of ₹636.88 Cr, a growth of 25% compared to the previous year. For the same year it recorded a net profit of ₹96.92 Cr (net margin 15.2%) and EBITDA of ₹160.57 Cr (EBITDA margin 25.2%). Revenue has grown at a compounded annual rate (CAGR) of 25% over three years and 21% over five years.

The company has about 552 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Flamingo Pharmaceuticals. As per MCA filings, the company has open charges of ₹121.37 Cr and satisfied charges of ₹452.45 Cr on record. Court records list 43 cases involving the company, including 7 filed by the company and 36 filed against it; 11 cases are pending. The company has 4 deals on record (3 secondary share transfers, 1 funding round), with disclosed funding of ₹4.54 Cr; the latest was in December 2024. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Kusum Healthcare Private Limited with revenue of ₹537.89 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website flamingopharma.com.

Company details

CIN U51900MH1985PLC036572
Registration Number 036572
Incorporation Date 12 June 1985
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant

Name history

Flamingo Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Flamingo Impex Limited, and Flamingo Impex P Limited. The current legal name is Flamingo Pharmaceuticals Limited.

Company NameStatus
Flamingo Pharmaceuticals LimitedCurrent
Flamingo Impex LimitedPrevious
Flamingo Impex P LimitedPrevious

Contact details

Flamingo Pharmaceuticals Limited's registered office is in Mumbai, Maharashtra. Its website is flamingopharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    7/1 Corporate Park Sion – Trombay Road P.O.Box No. : 27257, Chembur, Mumbai, Maharashtra, India – 400071
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Flamingo Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Flamingo Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Flamingo Pharmaceuticals operates one associated brand: Flamingo Pharmaceuticals. Each brand links to its own profile.

BrandDescriptionWebsite
Manufactures and distributes pharmaceutical products to over 50 countries worldwide.flamingopharma.com

Business activity

The main business activity of Flamingo Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Flamingo Pharmaceuticals Limited, buy the company report.

Financials of Flamingo Pharmaceuticals Limited

FY 2025 filings available

Flamingo Pharmaceuticals Limited reported revenue of ₹636.88 Cr (up 25% YoY) for FY 2026.

Revenue · FY 2026
₹636.88 Cr ▲ 25%
Net profit · FY 2026
₹96.92 Cr margin 15.2%
EBITDA · FY 2026
₹160.57 Cr margin 25.2%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 25%
3 years · compounded
▲ 25%
5 years · compounded
▲ 21%
EBITDA CAGR growth
1 year
▲ 45%
3 years · compounded
▲ 40%
5 years · compounded
▲ 16%

Revenue has grown at a compounded annual rate (CAGR) of 21% over five years, including 25% growth in the latest year. EBITDA rose 45% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹160.57 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹96.92 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profitability
EBITDA Margin25.2%
Net Profit Margin15.2%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Flamingo Pharmaceuticals Limited, buy the company report.

Board of directors and KMP of Flamingo Pharmaceuticals Limited

Flamingo Pharmaceuticals Limited currently reports 5 directors and 1 key managerial person. 23 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Sunil KumarCeo02 Aug 20233 Years 2 MonthsCurrent
Parth Ashwin ThackerDirector10 Nov 20232 Years 11 MonthsCurrent
Chhotulal Rawa BhagwatDirector25 Oct 20224 Years 0 MonthsCurrent
Pranay Ashwin ThackerDirector08 Jun 20215 Years 4 MonthsCurrent
Ashwin Jethalal ThackerDirector23 Jun 198640 Years 4 MonthsCurrent
Meena Sanjiv KapadiDirector28 Sep 20224 Years 0 MonthsCurrent

Peer comparison

Flamingo Pharmaceuticals Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Flamingo Pharmaceuticals Limitedthis company₹636.88 Cr (FY 2026)₹96.92 Cr15.2%25.0%552Mumbai, Maharashtra, India
Kusum Healthcare Private Limited₹537.89 Cr (FY 2025)10.0%New Delhi, Delhi, India
Unison Pharmaceuticals Private Limited₹537.1 Cr (FY 2025)23.0%Ahmedabad, Gujarat, India
Maneesh Pharmaceuticals Limited₹534.48 Cr (FY 2022)28.0%Mumbai, Maharashtra, India
Mapaex Health and Personalcare Private Limited₹514.15 Cr (FY 2024)23.0%Bhopal, Madhya Pradesh, India
Cronus Pharma Specialities India Private Limited₹484.74 Cr (FY 2025)64.0%Hyderabad, Telangana, India
Aarey Drugs and Pharmaceuticals Limited₹483.76 Cr (FY 2025)20.0%Thane, Maharashtra, India
Syncom Formulations (India) Limited₹482.45 Cr (FY 2025)74.0%Mumbai, Maharashtra, India
Karnataka Antibiotics and Pharmaceuticals Limited₹479.24 Cr (FY 2022)11.0%Bangalore, Karnataka, India

To see the full peer comparison of Flamingo Pharmaceuticals Limited, buy the company report.

Auditor

Flamingo Pharmaceuticals Limited is audited by Pravin Sarvaiya & Co. for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Pravin Sarvaiya & Co.FY 2023114753W

Shareholding

The shareholding of Flamingo Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2021FY 2020FY 2019FY 2018
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Flamingo Pharmaceuticals Limited, buy the company report.

Charges & borrowings

Open charges
₹121.37 Cr
Satisfied charges
₹452.45 Cr
Breakdown by lending institutions
Others₹104.37 Cr
Icici Bank Limited₹17.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
27 Feb 2023100691074Others₹22 LakhOpen
18 Nov 2022100651360Others₹18.15 CrOpen
22 Feb 2022100546326Others₹20 CrOpen
09 Oct 201510600162Others₹13 CrOpen
29 Sep 201510600160Others₹5 CrOpen

To see the full charge records of Flamingo Pharmaceuticals Limited, buy the company report.

Total charge records: 39 View all charges

Deals & funding

Flamingo Pharmaceuticals Limited has 4 deals on record (3 secondary share transfers, 1 funding round), with disclosed funding of ₹4.54 Cr; the latest was in December 2024.

Total deals
4
Secondary share transfers
3
Funding round
1
Disclosed funding
₹4.54 Cr

Deals on record (4 of 4)

WhenDealAmountParties
Dec 2024Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Sep 2023Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Mar 2016Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Mar 2008Funding round₹4.54 CrInvestors: Mini Med Laboratories Pvt Ltd , 3 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Flamingo Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Flamingo Pharmaceuticals Limited has a workforce of 552 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.

Employee count
552
Active EPFO establishments
1
Employee growth
-33.81%

GST

Flamingo Pharmaceuticals has 9 GST registrations: 1 active and 8 cancelled or inactive.

Total GSTINs
9
Active
1
Cancelled / inactive
8
GSTINStateStatusRegistered on
27AAACF4211B1ZEMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Flamingo Pharmaceuticals Limited, buy the company report.

Recent activity

Flamingo Pharmaceuticals Limited has 26 board changes on record since 1986: 6 appointments and 20 cessations. The latest: Parth Ashwin Thacker ceased to be Additional Director on 25 Sep 2024.

AGM
Flamingo Pharmaceuticals Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Flamingo Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge registered on 24 Jan 2024 via Charge ID 100923017 with Yes Bank Limited was fully satisfied on 17 Oct 2024.
Ceased
Parth Ashwin Thacker ceased to be Additional Director.
Charges
A charge with Others of Rs. 43.00 Cr registered on 18 Jun 2014 with Charge ID 10504887 was modified on 20 Jul 2024.
Charges
A charge with Yes Bank Limited amounted to Rs. 20.00 Cr with Charge ID 100923017 was registered on 24 Jan 2024.
Appointed
Parth Ashwin Thacker was appointed as Director.
Charges
A charge with Others of Rs. 18.15 Cr registered on 18 Nov 2022 with Charge ID 100651360 was modified on 26 Sep 2023.
Appointed
Sunil Kumar was appointed as CEO.
Ceased
Ashwin Jethalal Thacker ceased to be Managing Director.
Charges
A charge with Others of Rs. 13.00 Cr registered on 09 Oct 2015 with Charge ID 10600162 was modified on 16 May 2023.
Charges
A charge with Others amounted to Rs. 0.22 Cr with Charge ID 100691074 was registered on 27 Feb 2023.

102 earlier events are in the company report.

Frequently asked questions

Flamingo Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 June 1985 (41+ years old) and is registered under CIN U51900MH1985PLC036572.

Flamingo Pharmaceuticals has 6 current directors and KMP:

The latest financial statements of Flamingo Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Flamingo Pharmaceuticals is 27AAACF4211B1ZE, registered in Maharashtra. The company has 9 GST registrations in all, of which 1 is active and 8 are cancelled or inactive.

The CIN (Corporate Identification Number) of Flamingo Pharmaceuticals is U51900MH1985PLC036572. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Flamingo Pharmaceuticals has 43 court cases on record: 7 filed by the company and 36 filed against it. 11 are pending. Most are in the district courts.

Flamingo Pharmaceuticals was incorporated on 12 June 1985, making it 41+ years old. It is registered with the Registrar of Companies, Mumbai.

Flamingo Pharmaceuticals has 4 deals on record (3 secondary share transfers, 1 funding round), with disclosed funding of ₹4.54 Cr; the latest was in December 2024.

The peers of Flamingo Pharmaceuticals by revenue are Kusum Healthcare Private Limited, Unison Pharmaceuticals Private Limited, Maneesh Pharmaceuticals Limited, Mapaex Health and Personalcare Private Limited, Cronus Pharma Specialities India Private Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Parth Ashwin Thacker ceased to be Additional Director on 25 Sep 2024. Parth Ashwin Thacker was appointed as Director on 10 Nov 2023. Sunil Kumar was appointed as CEO on 02 Aug 2023. Flamingo Pharmaceuticals has 26 board changes on record in total.

Flamingo Pharmaceuticals can be reached through the website flamingopharma.com. Its registered office is in Mumbai, Maharashtra, India.